You'll have to ask your doctor about this.
http://www.hubmed.org/display.cgi?uids=22761293
Hemispatial neglect following right-hemisphere stroke is a common and
disabling disorder, for which there is currently no effective
pharmacological treatment. Dopamine agonists have been shown to play a
role in selective attention and working memory, two core cognitive
components of neglect. Here, we investigated whether the dopamine
agonist rotigotine would have a beneficial effect on hemispatial neglect
in stroke patients. A double-blind, randomized, placebo-controlled ABA
design was used, in which each patient was assessed for 20 testing
sessions, in three phases: pretreatment (Phase A1), on transdermal
rotigotine for 7-11 days (Phase B) and post-treatment (Phase A2), with
the exact duration of each phase randomized within limits. Outcome
measures included performance on cancellation (visual search), line
bisection, visual working memory, selective attention and sustained
attention tasks, as well as measures of motor control. Sixteen
right-hemisphere stroke patients were recruited, all of whom completed
the trial. Performance on the Mesulam shape cancellation task improved
significantly while on rotigotine, with the number of targets found on
the left side increasing by 12.8% (P = 0.012) on treatment and spatial
bias reducing by 8.1% (P = 0.016). This improvement in visual search was
associated with an enhancement in selective attention but not on our
measures of working memory or sustained attention. The positive effect
of rotigotine on visual search was not associated with the degree of
preservation of prefrontal cortex and occurred even in patients with
significant prefrontal involvement. Rotigotine was not associated with
any significant improvement in motor performance. This proof-of-concept
study suggests a beneficial role of dopaminergic modulation on visual
search and selective attention in patients with hemispatial neglect
following stroke.
No comments:
Post a Comment